Agenus is the lead sponsor of 3 current clinical trials in our USA, UK, Israel, France, Spain, Italy, Belgium, Brazil, Germany and Switzerland registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 2. The drugs named most often in its trials are Balstilimab and Botensilimab. The most-studied condition is Advanced Cancer.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272 · Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases
Drugs: Balstilimab, Botensilimab |
Phase 1 | Active, closed | 2019-03 | UK, USA, Israel |
|
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
NCT05529316 · Advanced Melanoma
Drugs: Balstilimab, Botensilimab |
Phase 2 | Active, closed | 2022-12 | UK, USA, Germany, France, Spain, Italy, Belgium, Switzerland, Brazil |
|
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
NCT05608044 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer
Drugs: Balstilimab, Botensilimab |
Phase 2 | Active, closed | 2022-11 | USA, France, Spain, Italy, Belgium, Brazil, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Agenus is the lead sponsor of 3 current trials on ClinicalTrials.gov in our USA, UK, Israel, France, Spain, Italy, Belgium, Brazil, Germany and Switzerland registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of its 3 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Its current trials name 2 drugs and biologicals as interventions. The most frequent are Balstilimab (3) and Botensilimab (3). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.